PTPRE

Summary

PTPRE (protein tyrosine phosphatase receptor type E, HGNC:9669) is a protein-coding gene on chromosome 10q26.2, encoding Receptor-type tyrosine-protein phosphatase epsilon (P23469). Isoform 1 plays a critical role in signaling transduction pathways and phosphoprotein network topology in red blood cells.

The protein encoded by this gene is a member of the protein tyrosine phosphatase (PTP) family. PTPs are known to be signaling molecules that regulate a variety of cellular processes including cell growth, differentiation, mitotic cycle, and oncogenic transformation. Several alternatively spliced transcript variants of this gene have been reported, at least two of which encode a receptor-type PTP that possesses a short extracellular domain, a single transmembrane region, and two tandem intracytoplasmic catalytic domains; another one encodes a PTP that contains a distinct hydrophilic N-terminus, and thus represents a nonreceptor-type isoform of this PTP. Studies of the similar gene in mice suggested the regulatory roles of this PTP in RAS related signal transduction pathways, cytokine-induced SATA signaling, as well as the activation of voltage-gated K+ channels.

Source: NCBI Gene 5791 — RefSeq curated summary.

At a glance

• GWAS associations: 3
• Clinical variants (ClinVar): 112 total — 2 pathogenic
• GTEx eGene: eQTL in 14 tissues, sQTL in 3 (q < 0.05)
• Constraint (gnomAD): pLI 0.00 (LoF-tolerant), LOEUF 0.64 (unconstrained)
• MANE Select transcript: NM_006504
• Notable: 112 clinical variants but no curated precision-oncology (CIViC) evidence yet

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:9669
Approved symbol	PTPRE
Name	protein tyrosine phosphatase receptor type E
Location	10q26.2
Locus type	gene with protein product
Status	Approved
Aliases	PTPE
Ensembl gene	ENSG00000132334
Ensembl biotype	protein_coding
OMIM	600926
Entrez	5791

Gene structure

Transcript identifiers

Ensembl transcripts: 26 — 21 protein_coding, 3 retained_intron, 2 nonsense_mediated_decay

MANE Select: ENST00000254667

Transcript support level (Ensembl TSL; 1 = fully mRNA-supported): TSL 1: 3, TSL 2: 2, TSL 3: 3, TSL 5: 3

ENST00000254667, ENST00000306042, ENST00000442830, ENST00000455661, ENST00000463727, ENST00000467366, ENST00000471218, ENST00000479896, ENST00000487428, ENST00000492479, ENST00000495530, ENST00000870711, ENST00000870712, ENST00000870713, ENST00000870714, ENST00000968589, ENST00000968590, ENST00000968591, ENST00000968592, ENST00000968593, ENST00000968594, ENST00000968595, ENST00000968596, ENST00000968597, ENST00000968598, ENST00001141502

RefSeq mRNA: 8 — MANE Select: NM_006504 NM_001316676, NM_001316677, NM_001323354, NM_001323355, NM_001323356, NM_001323357, NM_006504, NM_130435

CCDS: CCDS7657, CCDS7658

Canonical transcript exons

ENST00000254667 — 21 exons

Exon	Start	End
ENSE00001190473	127982274	127982296
ENSE00001190478	127907103	127907309
ENSE00001764214	128070808	128070901
ENSE00003480338	128079560	128079695
ENSE00003493715	128066075	128066194
ENSE00003497089	128047390	128047489
ENSE00003506468	128069692	128069827
ENSE00003511026	128073337	128073471
ENSE00003561179	128060939	128061015
ENSE00003561185	128068123	128068286
ENSE00003583220	128063083	128063180
ENSE00003617670	128070301	128070450
ENSE00003619320	128082832	128085855
ENSE00003634815	128077617	128077783
ENSE00003635913	128040875	128040990
ENSE00003665553	128072138	128072214
ENSE00003671504	128056123	128056213
ENSE00003673996	128076603	128076728
ENSE00003684247	128047764	128047837
ENSE00003692645	128061679	128061715
ENSE00003786459	128049530	128049666

Expression profiles

Bgee: expression breadth ubiquitous, 269 present calls, max score 96.37.

FANTOM5 (CAGE): breadth ubiquitous, TPM avg 39.4930 / max 4424.3553, expressed in 1379 samples.

Highest expression (Bgee): monocyte, mononuclear cell, leukocyte, blood, bone marrow cell.

Genetic regulation across tissues (GTEx eQTL / sQTL)

PTPRE is an eGene in GTEx v10 — its expression is genetically regulated (eQTL) in 14 tissues and its splicing (sQTL) in 3 (q < 0.05). Strongest associations first; slope = normalized effect of the lead variant’s alternative allele.

17 significant tissue × QTL associations:

Tissue	QTL	q-value	Slope	Lead variant
Whole Blood	sqtl	2.9e-20	+1.42	10:128052175:C:A
Cells Cultured fibroblasts	eqtl	7.6e-08	+0.23	10:127917495:G:A
Testis	eqtl	7.5e-05	-0.20	10:128059120:G:A
Esophagus Mucosa	eqtl	5.2e-04	-0.14	10:128048856:G:T
Brain Cerebellum	eqtl	1.5e-03	+0.43	10:127903946:G:T
Pituitary	eqtl	1.7e-03	-0.24	10:128005788:G:A
Skin Not Sun Exposed Suprapubic	eqtl	3.3e-03	+0.45	10:128526120:C:T
Whole Blood	eqtl	4.4e-03	+0.07	10:128073502:A:AG
Brain Cerebellar Hemisphere	eqtl	4.9e-03	+0.33	10:127925408:C:A
Heart Left Ventricle	eqtl	5.2e-03	+0.15	10:127917040:A:T
Nerve Tibial	sqtl	7.4e-03	+0.25	10:128073426:A:G
Artery Tibial	sqtl	7.6e-03	-0.39	10:128396561:G:A
Skin Sun Exposed Lower leg	eqtl	1.1e-02	+0.12	10:127946773:T:C
Lung	eqtl	1.8e-02	-0.09	10:128065142:AG:A
Esophagus Gastroesophageal Junction	eqtl	1.9e-02	+0.86	10:128211025:C:T
Brain Caudate basal ganglia	eqtl	3.3e-02	+0.26	10:126927823:A:G
Spleen	eqtl	4.6e-02	+0.12	10:127551524:T:C

FANTOM5 promoters

showing 10 of 11 alternative TSS:

Promoter ID	TPM avg	Samples expressed
107649	19.5882	688
107648	8.3824	648
107630	6.1254	1077
107650	2.0430	292
107640	1.1232	163
107631	1.0399	607
107647	0.8939	282
107643	0.1195	65
107641	0.0632	48
107628	0.0597	22

Top tissues by expression

showing 100 of 290 tissues by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
monocyte	CL:0000576	96.37	gold quality
mononuclear cell	CL:0000842	96.37	gold quality
leukocyte	CL:0000738	96.25	gold quality
blood	UBERON:0000178	95.70	gold quality
bone marrow cell	CL:0002092	95.47	gold quality
granulocyte	CL:0000094	94.55	gold quality
bone marrow	UBERON:0002371	94.09	gold quality
sural nerve	UBERON:0015488	93.16	gold quality
visceral pleura	UBERON:0002401	92.18	gold quality
bone element	UBERON:0001474	91.81	gold quality
trigeminal ganglion	UBERON:0001675	90.41	gold quality
right lung	UBERON:0002167	90.02	gold quality
vermiform appendix	UBERON:0001154	89.94	gold quality
pleura	UBERON:0000977	89.77	gold quality
upper lobe of left lung	UBERON:0008952	89.31	gold quality
decidua	UBERON:0002450	89.14	gold quality
upper lobe of lung	UBERON:0008948	89.14	gold quality
CA1 field of hippocampus	UBERON:0003881	88.89	gold quality
spleen	UBERON:0002106	88.45	gold quality
parietal pleura	UBERON:0002400	88.01	gold quality
caecum	UBERON:0001153	87.79	gold quality
right adrenal gland cortex	UBERON:0035827	87.79	gold quality
trabecular bone tissue	UBERON:0002483	87.73	gold quality
adrenal cortex	UBERON:0001235	87.59	gold quality
left adrenal gland cortex	UBERON:0035825	87.47	gold quality
left adrenal gland	UBERON:0001234	87.42	gold quality
lower lobe of lung	UBERON:0008949	87.41	gold quality
lung	UBERON:0002048	87.37	gold quality
middle temporal gyrus	UBERON:0002771	87.37	gold quality
right adrenal gland	UBERON:0001233	87.18	gold quality
adrenal gland	UBERON:0002369	87.15	gold quality
corpus callosum	UBERON:0002336	87.00	gold quality
Brodmann (1909) area 23	UBERON:0013554	86.78	gold quality
ileal mucosa	UBERON:0000331	86.27	gold quality
buccal mucosa cell	CL:0002336	86.22	gold quality
cartilage tissue	UBERON:0002418	86.22	gold quality
lymph node	UBERON:0000029	86.02	gold quality
periodontal ligament	UBERON:0008266	85.46	gold quality
postcentral gyrus	UBERON:0002581	84.78	gold quality
dorsal root ganglion	UBERON:0000044	84.72	gold quality
parietal lobe	UBERON:0001872	84.69	gold quality
peritoneum	UBERON:0002358	84.42	gold quality
omental fat pad	UBERON:0010414	84.42	gold quality
mammary duct	UBERON:0001765	84.35	gold quality
epithelium of mammary gland	UBERON:0003244	84.29	gold quality
germinal epithelium of ovary	UBERON:0001304	84.20	gold quality
Ammon’s horn	UBERON:0001954	84.16	gold quality
C1 segment of cervical spinal cord	UBERON:0006469	84.09	gold quality
spinal cord	UBERON:0002240	84.00	gold quality
adipose tissue of abdominal region	UBERON:0007808	83.96	gold quality
subthalamic nucleus	UBERON:0001906	83.92	gold quality
Brodmann (1909) area 46	UBERON:0006483	83.81	gold quality
orbitofrontal cortex	UBERON:0004167	83.68	gold quality
upper leg skin	UBERON:0004262	83.52	gold quality
rectum	UBERON:0001052	83.34	gold quality
male germ line stem cell (sensu Vertebrata) in testis	CL:0000089 ∩ UBERON:0000473	83.33	gold quality
tibial nerve	UBERON:0001323	83.29	gold quality
inferior vagus X ganglion	UBERON:0005363	83.27	gold quality
superior frontal gyrus	UBERON:0002661	83.23	gold quality
occipital lobe	UBERON:0002021	83.08	gold quality
primary visual cortex	UBERON:0002436	82.97	gold quality
choroid plexus epithelium	UBERON:0003911	82.70	gold quality
duodenum	UBERON:0002114	82.62	gold quality
prefrontal cortex	UBERON:0000451	82.61	gold quality
gall bladder	UBERON:0002110	82.61	gold quality
heart left ventricle	UBERON:0002084	82.58	gold quality
pericardium	UBERON:0002407	82.58	gold quality
cardiac ventricle	UBERON:0002082	82.44	gold quality
thoracic mammary gland	UBERON:0005200	82.42	gold quality
small intestine	UBERON:0002108	82.31	gold quality
mammary gland	UBERON:0001911	82.25	gold quality
adrenal tissue	UBERON:0018303	82.24	gold quality
entorhinal cortex	UBERON:0002728	82.23	gold quality
small intestine Peyer’s patch	UBERON:0003454	82.19	gold quality
mammalian vulva	UBERON:0000997	81.91	gold quality
temporal lobe	UBERON:0001871	81.85	gold quality
superior vestibular nucleus	UBERON:0007227	81.81	gold quality
dorsolateral prefrontal cortex	UBERON:0009834	81.74	gold quality
subcutaneous adipose tissue	UBERON:0002190	81.64	gold quality
medulla oblongata	UBERON:0001896	81.60	gold quality
descending thoracic aorta	UBERON:0002345	81.43	gold quality
skin of hip	UBERON:0001554	81.40	gold quality
amygdala	UBERON:0001876	81.38	gold quality
hypothalamus	UBERON:0001898	81.37	gold quality
Brodmann (1909) area 9	UBERON:0013540	81.37	gold quality
palpebral conjunctiva	UBERON:0001812	81.29	gold quality
cerebral cortex	UBERON:0000956	81.16	gold quality
adipose tissue	UBERON:0001013	81.11	gold quality
connective tissue	UBERON:0002384	81.10	gold quality
right coronary artery	UBERON:0001625	81.04	gold quality
cingulate cortex	UBERON:0003027	81.02	gold quality
frontal cortex	UBERON:0001870	80.82	gold quality
transverse colon	UBERON:0001157	80.81	gold quality
intestine	UBERON:0000160	80.78	gold quality
esophagus mucosa	UBERON:0002469	80.75	gold quality
anterior cingulate cortex	UBERON:0009835	80.74	gold quality
pons	UBERON:0000988	80.73	gold quality
mucosa of sigmoid colon	UBERON:0004993	80.73	gold quality
colonic epithelium	UBERON:0000397	80.68	gold quality
heart right ventricle	UBERON:0002080	80.66	gold quality

Single-cell (SCXA)

Detected in 25 experiment(s), a significant marker in 25.

Experiment	Marker?	Max mean expression
E-GEOD-131882	yes	1152.79
E-CURD-11	yes	524.05
E-CURD-122	yes	82.11
E-HCAD-4	yes	37.47
E-MTAB-8142	yes	35.10
E-MTAB-10553	yes	33.90
E-HCAD-6	yes	33.16
E-MTAB-10287	yes	23.67
E-HCAD-13	yes	22.66
E-HCAD-1	yes	21.16
E-MTAB-9221	yes	20.84
E-MTAB-6701	yes	18.18
E-MTAB-9467	yes	15.56
E-CURD-46	yes	14.59
E-CURD-112	yes	13.65

HPA expression

RNA tissue specificity: Tissue enhanced

showing 60 of 79 HPA tissues / cells by nTPM:

Tissue / cell	Axis	nTPM	Protein (IHC)
Bone marrow	tissue	44.3	medium
Hippocampus	tissue	37.4	not detected
Choroid plexus	tissue	26.7
Postcentral gyrus	tissue	26.3
Appendix	tissue	23.8	high
Locus coeruleus	tissue	22.9
Nucleus accumbens	tissue	21.3
Hippocampal formation	tissue	19.8
Prefrontal cortex	tissue	19.6
Cerebral cortex	tissue	19.6	not detected
Motor cortex	tissue	19.4
Amygdala	tissue	19.4
Spleen	tissue	19.4	high
Cerebellum	tissue	18.8	low
Ventral forebrain	tissue	18.2
Basal ganglia	tissue	18.1	not detected
Insular cortex	tissue	17.2
Spinal cord	tissue	17.1
Retrosplenial and cingulate cortex	tissue	16.9
Retrosplenial cortex	tissue	16.8
Temporal cortex	tissue	16.3
Lymph node	tissue	15.3	high
Lung	tissue	15.1	high
Entorhinal cortex	tissue	15.0
Septum	tissue	14.9
Somatosensory cortex	tissue	14.9
Putamen	tissue	14.8
Adrenal gland	tissue	13.7	high
Occipital cortex	tissue	13.4
Adipose tissue	tissue	12.7	medium
Caudate putamen	tissue	12.4
Hypothalamus	tissue	12.3
Small intestine	tissue	12.2	medium
Urinary bladder	tissue	11.9	low
Substantia nigra	tissue	11.0
Medulla oblongata	tissue	10.7
Periaqueductal gray	tissue	10.6
Thalamus	tissue	9.8
Superior colliculi	tissue	9.7
Gallbladder	tissue	9.6	medium
Tonsil	tissue	9.2	high
Pons	tissue	9.0
Duodenum	tissue	9.0	not detected
Rectum	tissue	8.8	medium
Midbrain	tissue	8.8
Colon	tissue	8.7	low
Heart muscle	tissue	8.4	medium
Thymus	tissue	8.0
Frontal cortex	tissue	7.6
Corpus callosum	tissue	7.6
Placenta	tissue	7.3	low
Stomach 1	tissue	7.0	medium
Smooth muscle	tissue	6.9	medium
Olfactory bulb	tissue	6.6
Breast	tissue	6.2	not detected
Esophagus	tissue	5.3	not detected
Pituitary gland	tissue	4.8
Skin 1	tissue	4.2	high
Vagina	tissue	4.1	not detected
Liver	tissue	4.1	low

Brain sub-regions (HPA Brain Atlas): detected in 191; highest nTPM — Lateral funiculus (white matter) (40.6), Area parastriata, superior (40.1), Hippocampus, CA1 (40.1), Hippocampus, CA3 (39.6), Corticomedial amygdala (39.2).

Regulation

Is transcription factor: no

Upstream regulators (CollecTRI, top): SPI1

miRNA regulators (miRDB)

Targeting PTPRE by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific).

showing 30 of 157 miRNAs:

miRNA	Max score	Avg score	miRNA target_count
HSA-LET-7A-3P	100.00	74.03	3932
HSA-LET-7B-3P	100.00	74.08	3913
HSA-LET-7F-1-3P	100.00	74.02	3928
HSA-MIR-98-3P	100.00	74.08	3907
HSA-MIR-1277-5P	100.00	73.95	5056
HSA-MIR-5011-5P	100.00	83.46	5820
HSA-MIR-340-5P	100.00	72.50	4437
HSA-MIR-1252-5P	100.00	69.80	2774
HSA-MIR-656-3P	100.00	72.15	2788
HSA-MIR-3613-3P	100.00	76.36	7965
HSA-MIR-4262	100.00	73.26	3931
HSA-MIR-4283	100.00	66.42	2097
HSA-MIR-432-3P	100.00	67.86	705
HSA-MIR-186-5P	99.99	70.83	3707
HSA-MIR-181A-5P	99.99	72.96	2995
HSA-MIR-181B-5P	99.99	72.97	2996
HSA-MIR-181C-5P	99.99	72.95	2996
HSA-MIR-181D-5P	99.99	73.04	2997
HSA-MIR-520D-5P	99.98	73.34	4883
HSA-MIR-524-5P	99.98	73.43	4882
HSA-MIR-12136	99.98	72.81	5713
HSA-MIR-4789-5P	99.98	70.76	2721
HSA-MIR-5696	99.98	72.36	4487
HSA-MIR-4803	99.98	71.99	3117
HSA-MIR-548N	99.98	71.94	4170
HSA-MIR-302C-5P	99.97	72.56	3642
HSA-MIR-3148	99.97	75.06	6478
HSA-MIR-3688-3P	99.97	72.02	2834
HSA-MIR-3065-5P	99.97	71.56	3281
HSA-MIR-5688	99.96	73.23	4504

Functional genomics

gnomAD constraint: pLI 4.5e-06, LOEUF 0.635, missense Z 2.35 — population loss-of-function intolerance (pLI ≥ 0.9 = LoF-intolerant; lower LOEUF = more constrained). gnomAD

Regional missense constraint (gnomAD)

ENST00000254667 splits into 2 regions with different missense tolerance; 0 are missense-constrained. Missense variants in a constrained region (low observed/expected) are more likely to be pathogenic. gnomAD

Region (GRCh38)	Missense obs / exp	o/e	Constrained
10:128,040,882–128,047,764	116 / 90.8	1.28	no
10:128,047,765–128,082,903	636 / 824.4	0.77	no

Literature-anchored findings (GeneRIF, showing 12)

• Transfection of cells with different PTPepsilon constructs and activator protein-1 reporter gene indicates that the catalytic activity of PTPepsilon is involved in the regulation of the mitogen-activated protein kinase cascade. (PMID:12121439)
• Characterization, expression and functional aspects of an alternative spliced isoform of protein tyrosine phosphatase epsilon (PMID:12193229)
• interactions between RPTP-domain1s and RPTP-domain 2s are a common but specific mechanism that is likely to be regulated- domain2s and the wedge structures are crucial determinants of binding specificity, thus regulating cross-talk between RPTPs (PMID:12376545)
• Functions to prevent inappropriate activation and to terminate prolonged, rather than acute, activation of ERK in the cytosol. (PMID:12754301)
• cyt-PTP epsilon is dimerized and phosphorylated in the absence of direct interaction between the PTP and extracellular molecules (PMID:12861030)
• Transgenic mice overexpressing catalytically inactive transmembrane protein tyrosine phosphatase epsilon provide unexpected insight into the cell-cell interactions that occur between oligodendrocytes and the cells which they myelinate. (PMID:15390114)
• Protein-tyrosine phosphatase epsilon regulates Shc signaling in a kinase-specific manner: increasing coherence in tyrosine phosphatase signaling (PMID:18093973)
• Studies indicate that RAD50 and PTPRE of crude associations with asthma at a Bonferroni-corrected level of significance, while IL4R, CCL5 and TBXA2R of nominal significance. (PMID:21734400)
• Epidermal growth factor receptor (EGFR)-mediated positive feedback of protein-tyrosine phosphatase epsilon (PTPepsilon) on ERK1/2 and AKT protein pathways is required for survival of human breast cancer cells. (PMID:22117074)
• these data demonstrate that HCV infection reduces PTPRE expression in the liver and peripheral blood mononuclear cell sof infected humans (PMID:28235043)
• RPTPepsilon promotes M2-polarized macrophage migration through ROCK2 signaling and podosome formation. (PMID:31722979)
• Receptor Type Protein Tyrosine Phosphatase Epsilon (PTPRE) Plays an Oncogenic Role in Thyroid Carcinoma by Activating the AKT and ERK1/2 Signaling Pathway. (PMID:36654463)

Cross-species orthologs

4 orthologs

Organism	Symbol	Gene ID
danio_rerio	ptprea	ENSDARG00000015891
danio_rerio	ptpreb	ENSDARG00000021151
mus_musculus	Ptpre	ENSMUSG00000041836
rattus_norvegicus	Ptpre	ENSRNOG00000015717

Paralogs (35): PTPRN (ENSG00000054356), PTPRU (ENSG00000060656), PTPN3 (ENSG00000070159), PTPN21 (ENSG00000070778), PTPN18 (ENSG00000072135), PTPN23 (ENSG00000076201), PTPRH (ENSG00000080031), PTPRC (ENSG00000081237), PTPN4 (ENSG00000088179), PTPRS (ENSG00000105426), PTPRZ1 (ENSG00000106278), PTPN5 (ENSG00000110786), PTPN6 (ENSG00000111679), PTPRB (ENSG00000127329), PTPN12 (ENSG00000127947), PTPRA (ENSG00000132670), PTPN22 (ENSG00000134242), PTPRF (ENSG00000142949), PTPN7 (ENSG00000143851), PTPRG (ENSG00000144724), PTPRJ (ENSG00000149177), PTPRO (ENSG00000151490), PTPN14 (ENSG00000152104), PTPRK (ENSG00000152894), PTPRR (ENSG00000153233), PTPRD (ENSG00000153707), PTPRN2 (ENSG00000155093), PTPN13 (ENSG00000163629), PTPN9 (ENSG00000169410), PTPRM (ENSG00000173482), PTPN2 (ENSG00000175354), PTPN11 (ENSG00000179295), PTPRT (ENSG00000196090), PTPN1 (ENSG00000196396), PTPN20 (ENSG00000204179)

Mouse-model phenotypes

Observed phenotypes of the mouse ortholog (MGI:97813) from MGI (Alliance of Genome Resources) — knockout/mutant phenotypes, ranked by annotation count. 9 distinct phenotype terms.

Mouse phenotype (MP)	Records
demyelination	1
abnormal osteoclast physiology	1
abnormal channel response	1
long tibia	1
abnormal osteoclast differentiation	1
increased bone trabecula number	1
increased trabecular bone volume	1
decreased circulating type I collagen C-terminal telopeptide level	1
abnormal podosome assembly	1

Additional cross-species homologs

Sequence homologs in species beyond Ensembl Compara’s model organisms, by Diamond local protein alignment (% sequence identity; best hit per species). Lower-identity rows are more distant homologs. The matched accessions’ gene symbols aren’t in biobtree yet, so each row shows the UniProt accession.

Organism	UniProt	Identity	Method
Gallus gallus	Q90687	98.3%	Diamond
Bos taurus	A7MBJ4	95.7%	Diamond
Macaca nemestrina	O02695	94.4%	Diamond
Styela plicata	P28205	93.9%	Diamond
Aedes aegypti	A0A6I8TCE0	89.3%	Diamond
Culex quinquefasciatus	B0X4T2	89.3%	Diamond
Drosophila melanogaster	P16621	86.8%	Diamond
Drosophila virilis	Q24708	74.6%	Diamond
Microplitis demolitor bracovirus (isolate Webb)	Q5I154	100.0%	Diamond

Genomic neighbors (locus context)

Genes flanking this one on the chromosome (NCBI/Entrez gene neighborhood). Positional context only — some neighbors share regulatory elements (bidirectional promoters, antisense/overlapping transcripts), but chromosomal adjacency is not itself a functional relationship (see Interactions for that).

Symbol	Type	Entrez
CLRN3	protein-coding	119467
PTPRE-AS1	ncRNA	124902557
FOXI2	protein-coding	399823
NPS	protein-coding	594857
AS-PTPRE	ncRNA	105378553
MKI67	protein-coding	4288
LINC01163	ncRNA	101927381

Protein

Protein identifiers

Receptor-type tyrosine-protein phosphatase epsilon — P23469 (reviewed: P23469)

All UniProt accessions (7): P23469, Q5VWH5, Q5VWH6, S4R2Y5, S4R3B0, S4R3X3, S4R448

UniProt curated annotations — full annotation on UniProt →

Function. Isoform 1 plays a critical role in signaling transduction pathways and phosphoprotein network topology in red blood cells. May play a role in osteoclast formation and function. Isoform 2 acts as a negative regulator of insulin receptor (IR) signaling in skeletal muscle. Regulates insulin-induced tyrosine phosphorylation of insulin receptor (IR) and insulin receptor substrate 1 (IRS-1), phosphorylation of protein kinase B and glycogen synthase kinase-3 and insulin induced stimulation of glucose uptake. Isoform 1 and isoform 2 act as a negative regulator of FceRI-mediated signal transduction leading to cytokine production and degranulation, most likely by acting at the level of SYK to affect downstream events such as phosphorylation of SLP76 and LAT and mobilization of Ca(2+).

Subunit / interactions. Monomer. Isoform 2: Homodimer. Can form oligomers. Dimerization is increased by oxidative stress and decreased by EGFR. Isoform 2 interacts with GRB2.

Subcellular location. Cell membrane Cytoplasm Cytoplasm.

Tissue specificity. Expressed in giant cell tumor (osteoclastoma rich in multinucleated osteoclastic cells).

Post-translational modifications. A catalytically active cytoplasmic form (p65) is produced by proteolytic cleavage of either isoform 1, isoform 2 or isoform 3. Isoform 1 and isoform 2 are phosphorylated on tyrosine residues by tyrosine kinase Neu. Isoform 1 is glycosylated.

Domain organisation. The tyrosine-protein phosphatase 2 domain (D2) mediates dimerization. The extreme N- and C- termini of the D2 domain act to inhibit dimerization and removal of these sequences increases dimerization and inhibits enzyme activity.

Induction. Up-regulated by 12-O-tetradecanoylphorbol-13-acetate (TPA) in HL-60 cells.

Miscellaneous. Produced by alternative promoter usage. Produced by alternative promoter usage. Produced by alternative initiation at Met-86 of isoform 1.

Similarity. Belongs to the protein-tyrosine phosphatase family. Receptor class 4 subfamily.

Isoforms (3)

UniProt ID	Names	Canonical?
P23469-1	1, PTPeM, RPTPe, tm-PTPe	yes
P23469-2	2, PTPeC, cyt-PTPe
P23469-3	3, p67

RefSeq proteins (8): NP_001303605, NP_001303606, NP_001310283, NP_001310284, NP_001310285, NP_001310286, NP_006495, NP_569119 (=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR000242	PTP_cat	Domain
IPR000387	Tyr_Pase_dom	Domain
IPR003595	Tyr_Pase_cat	Domain
IPR016130	Tyr_Pase_AS	Active_site
IPR016336	Tyr_Pase_rcpt_a/e-type	Family
IPR029021	Prot-tyrosine_phosphatase-like	Homologous_superfamily
IPR050348	Protein-Tyr_Phosphatase	Family

Pfam: PF00102

Enzyme classification (BRENDA)

• EC 3.1.3.48 — protein-tyrosine-phosphatase (BRENDA: 59 organisms, 501 substrates, 1326 inhibitors, 270 Km, 165 kcat entries)

Substrate kinetics (BRENDA)

70 substrates with measured Km, best-characterized 15. Km ranges are aggregated across organisms/conditions.

Substrate	Km (mM)	Measurements
4-NITROPHENYL PHOSPHATE	0.0008–148	84
6,8-DIFLUORO-4-METHYLUMBELLIFERYL PHOSPHATE	0.0039–0.862	27
P-NITROPHENYL PHOSPHATE	0.0024–10	20
DADEPYLIPQQG	0.0003–0.1	12
PHOSPHOTYROSINE	0.012–30	11
LYSOZYME	0.0003–0.012	5
MYELIN BASIC PROTEIN	0.0001–0.022	5
ACETYL-DADEPY-NH2	0.0228–0.219	4
ACETYL-DADEPYL-NH2	1.1–97.5	4
4,6,8-TRIMETHYL-2-OXO-2H-CHROMEN-7-YL DIHYDROGEN	0.02–0.156	3
SASASPYSASA	0.53–2.3	3
1-NAPHTHYL PHOSPHATE	1.19–1.88	2
3,6-FLUORESCEIN DIPHOSPHATE	15–19	2
4-METHYLUMBELLIFERYL PHOSPHATE	0.953–2.41	2
BOVINE SERUM ALBUMIN	0.0001–0.0003	2

Catalyzed reactions (Rhea)

• O-phospho-L-tyrosyl-[protein] + H2O = L-tyrosyl-[protein] + phosphate (RHEA:10684)

UniProt features (76 total): strand 28, helix 24, turn 6, binding site 3, glycosylation site 2, splice variant 2, topological domain 2, domain 2, active site 2, signal peptide 1, chain 1, modified residue 1, sequence conflict 1, transmembrane region 1

Structure

Experimental structures (PDB)

4 structures by resolution:

PDB	Title	Method	Resolution (Å)
6D4D	Crystal structure of the PTP epsilon D1 domain	X-RAY DIFFRACTION	1.76
6D4F	Crystal structure of PTP epsilon D2 domain (A455N/V457Y/E597D)	X-RAY DIFFRACTION	1.91
6D3F	Crystal Structure of the PTP epsilon D2 domain	X-RAY DIFFRACTION	2.27
2JJD	Protein Tyrosine Phosphatase, Receptor Type, E isoform	X-RAY DIFFRACTION	3.2

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-P23469-F1	86.42	0.74

Human Protein Atlas

Protein class: Enzymes, ENZYME proteins, Hydrolases, Predicted membrane proteins, Predicted intracellular proteins

Protein evidence: Evidence at protein level

Subcellular location (HPA, imaging): intermediate filaments

Antibody reliability (HPA): IH supported · IF approved

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Catalytic / active sites (2)

Position	Role
335	phosphocysteine intermediate
630	phosphocysteine intermediate

Ligand- & substrate-binding residues (3)

Position	Role
335–341	substrate
379	substrate
303	substrate

Post-translational modifications (1)

Type	Positions
Phosphotyrosine	696

Glycosylation sites (2)

Type	Positions
N-linked (glcnac…) asparagine	23, 30

Function

Pathways and Gene Ontology

Reactome pathways

0 curated (TAS) of 0; 0 disease pathways. Curated-first; evidence = TAS (manually curated) vs IEA (electronic inference).

MSigDB gene sets: 431 (showing top): GSE45365_NK_CELL_VS_CD8_TCELL_DN, GOBP_REGULATION_OF_CELL_ACTIVATION, RNGTGGGC_UNKNOWN, GOBP_RESPONSE_TO_NITROGEN_COMPOUND, YAGI_AML_WITH_INV_16_TRANSLOCATION, ENK_UV_RESPONSE_KERATINOCYTE_UP, MODULE_45, MODULE_64, GOBP_NEGATIVE_REGULATION_OF_CELLULAR_RESPONSE_TO_INSULIN_STIMULUS, LINDGREN_BLADDER_CANCER_CLUSTER_3_DN, BROWNE_HCMV_INFECTION_16HR_UP, GOBP_CELLULAR_RESPONSE_TO_OXYGEN_CONTAINING_COMPOUND, GOBP_CELLULAR_RESPONSE_TO_INSULIN_STIMULUS, ATGTTAA_MIR302C, BILD_HRAS_ONCOGENIC_SIGNATURE

GO Biological Process (5): protein dephosphorylation (GO:0006470), signal transduction (GO:0007165), regulation of mast cell activation (GO:0033003), negative regulation of insulin receptor signaling pathway (GO:0046627), dephosphorylation (GO:0016311)

GO Molecular Function (6): protein tyrosine phosphatase activity (GO:0004725), transmembrane receptor protein tyrosine phosphatase activity (GO:0005001), identical protein binding (GO:0042802), phosphoprotein phosphatase activity (GO:0004721), protein binding (GO:0005515), hydrolase activity (GO:0016787)

GO Cellular Component (3): nucleus (GO:0005634), cytoplasm (GO:0005737), plasma membrane (GO:0005886)

GO top-level categories

27 GO namespaces:

Category	Terms
dephosphorylation	1
protein modification process	1
cell communication	1
cellular process	1
signaling	1
regulation of cellular process	1
cellular response to stimulus	1
regulation of leukocyte activation	1
mast cell activation	1
insulin receptor signaling pathway	1
negative regulation of signal transduction	1
regulation of insulin receptor signaling pathway	1
negative regulation of cellular response to insulin stimulus	1
phosphate-containing compound metabolic process	1
phosphoprotein phosphatase activity	1
protein tyrosine phosphatase activity	1
transmembrane receptor protein phosphatase activity	1
protein binding	1
phosphatase activity	1
catalytic activity, acting on a protein	1
binding	1
catalytic activity	1
intracellular membrane-bounded organelle	1
intracellular anatomical structure	1
cellular anatomical structure	1
membrane	1
cell periphery	1

Experimentally-supported GO annotations

GO terms backed by direct experimental evidence (ECO experimental codes) — 3 of 14 annotations. The rest are phylogenetic / computational / electronic (IEA).

3 experimentally-supported GO terms:

GO term	NS	Evidence
cytoplasm	CC	direct assay
nucleus	CC	direct assay
plasma membrane	CC	direct assay

Protein interactions and networks

STRING

showing 15 of 1,022 interactions by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
PTPRE	PTS	Q03393	588
PTPRE	MTMR9	Q96QG7	465
PTPRE	EEF1E1	O43324	406
PTPRE	RIPOR3	Q96MK2	370
PTPRE	GCSAML	Q5JQS6	370
PTPRE	CALHM3	Q86XJ0	370
PTPRE	DGKH	Q86XP1	370
PTPRE	PITPNC1	Q9UKF7	370
PTPRE	FLAD1	Q8NFF5	367
PTPRE	PTPRJ	Q12913	365
PTPRE	ARHGAP6	O43182	362
PTPRE	FGFRL1	Q8N441	362
PTPRE	UBOX5	O94941	358
PTPRE	DPM1	O60762	357
PTPRE	ZNF367	Q7RTV3	357

IntAct

Human interaction partners of PTPRE in IntAct, one row per partner (best MIscore; records = supporting IntAct interaction records).

9 partners by confidence:

Partner	Interaction type	MIscore	Records
PTPRA	association	0.640	2
FYN	physical association	0.400	1
EGFR	physical association	0.370	1
NLRP12	physical association	0.370	1
KIF1B	association	0.350	1
XPO1	association	0.350	1
YES1	association	0.350	1
DLG1	proximity	0.270	1
PDGFRB	dephosphorylation reaction	0.000	1

BioGRID (82 interactions; top human partners by supporting records): PTPRA (Affinity Capture-MS; 7 records), GRB2 (Affinity Capture-MS; 4 records), CANX (Affinity Capture-MS; 2 records), CSE1L (Affinity Capture-MS; 2 records), KCNB1 (Affinity Capture-Western; 2 records), SAAL1 (Affinity Capture-MS; 2 records), XPO1 (Affinity Capture-MS; 2 records), XPO4 (Affinity Capture-MS; 2 records), ABI2 (Proximity Label-MS), ATP5O (Affinity Capture-MS), ATP6V0C (Affinity Capture-MS), BAIAP2 (Proximity Label-MS), BZW2 (Affinity Capture-MS), CAMK2G (Negative Genetic), CERS2 (Affinity Capture-MS)

SIGNOR signaling

showing 4 of 8 signaling interactions:

A	Effect	B	Mechanism
PTPRE	“down-regulates activity”	MAPK1	dephosphorylation
PTPRE	“down-regulates activity”	KCNB1	dephosphorylation
PTPRE	“down-regulates activity”	INSR	dephosphorylation
PTPRE	“up-regulates activity”	SRC	dephosphorylation

Disease & clinical

Genetic variants

Variant evidence for PTPRE: 112 ClinVar records (2 pathogenic / likely pathogenic); 3 GWAS associations. Per-variant detail is on Sugi Variant.

ClinVar

112 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	2
Likely pathogenic	0
Uncertain significance	82
Likely benign	6
Benign	0

Top pathogenic / likely-pathogenic (2)

Showing all 2 pathogenic / likely-pathogenic ClinVar records, ranked by ClinVar review status (expert panel → multiple submitters → single submitter), then by number of submitting labs.

Variant ID	HGVS	Classification	Review	Submitters
146431	GRCh38/hg38 10q26.2-26.3(chr10:127640489-132776585)x1	Pathogenic	no assertion criteria provided	1
153718	GRCh38/hg38 10q26.11-26.3(chr10:119707856-133613639)x3	Pathogenic	no assertion criteria provided	1

Per-variant reference — Sugi Variant

Explore PTPRE’s pathogenic and likely-pathogenic variants individually — each with its ClinVar classification and conditions, applied ACMG criteria (ClinGen expert panel, where curated), the calibrated in-silico predictors (AlphaMissense, REVEL, SaProt, conservation), gnomAD frequency, and the predictor-disagreement QC signal — on Sugi Variant.

SpliceAI

Top 10 splice-impact sites by Δscore (adjacent positions with the same effect merged into one range; 36 predictions of 2,360):

Position(s)	Effect	Δscore	Sites
10:128040991–128040992	donor_loss	1.0000	4
10:128047490–128047491	donor_loss	1.0000	5
10:128047762	acceptor_gain	1.0000
10:128047762–128047763	acceptor_loss	1.0000	5
10:128047838–128047839	donor_loss	1.0000	3
10:128049527	acceptor_gain	1.0000
10:128049528–128049529	acceptor_loss	1.0000	6
10:128049667–128049668	donor_loss	1.0000	5
10:128063078	acceptor_gain	1.0000
10:128063081–128063082	acceptor_loss	1.0000	5

AlphaMissense

2,151 missense substitutions predicted likely pathogenic (of 4,652 scored), across 470 residues. Top 20 hotspot residues, ranked by the number of likely-pathogenic substitutions (of those reachable by a single-nucleotide change), then by mean score:

Residue	Likely-pathogenic substitutions	Mean am_pathogenicity	Max am_pathogenicity
M232	9	0.959	0.997
M443	9	0.940	0.995
D657	8	0.995	0.998
N163	8	0.994	0.999
D303	8	0.994	0.999
H334	8	0.993	0.999
S336	8	0.992	0.999
H629	8	0.972	0.997
S631	8	0.969	0.998
F386	8	0.968	0.997
D271	8	0.967	0.994
D480	8	0.965	0.996
H671	8	0.965	0.997
F316	8	0.964	0.999
N451	8	0.962	0.999
F699	8	0.962	0.996
F659	8	0.961	0.996
F640	8	0.960	0.998
F298	8	0.959	0.999
D509	8	0.956	0.987

HPA cancer prognostics

RNA cancer specificity: Low cancer specificity

Human Protein Atlas survival analysis — favorable = higher expression predicts better survival.

3 prognostic cancer types:

Cancer	Prognostic	p-value
Pancreatic Adenocarcinoma (validation)	unfavorable	1.97e-05
Uterine Corpus Endometrial Carcinoma (TCGA)	unfavorable	6.24e-05
Kidney Renal Clear Cell Carcinoma (TCGA)	favorable	0.000805

Disease associations

OMIM: gene MIM:600926 | disease phenotypes:

GWAS associations

3 associations:

Study	Trait	p-value
GCST009615_12	Triglyceride levels x loop diuretics use interaction	5e-7
GCST000083_2	Select biomarker traits	1e-6
GCST001651_79	Response to amphetamines	7e-6

EFO canonical traits (from GWAS)

2 canonical traits:

EFO ID	Trait name
EFO:0004618	vitamin K measurement
EFO:0004530	triglyceride measurement

Drugs & pharmacology

Drug and pharmacology data

Is drug target: yes

ChEMBL targets (1): CHEMBL4850 (SINGLE PROTEIN)

PharmGKB: 1 entry (CPIC guideline: no)

GtoPdb / IUPHAR curated pharmacology

(IUPHAR/BPS Guide to Pharmacology — expert-curated)

Target class: catalytic receptor — Receptor tyrosine phosphatase (RTP) family

Binding affinities (BindingDB)

26 measured of 55 human assays (58 total across all organisms); most potent 26 below. Values come from heterogeneous assays and are not directly comparable.

Ligand	Measure	Value	Patent
(1S,2R,4aS,6aS,6bR,8aR,10R,11R,12aR,12bR,14bS)-10,11-dihydroxy-1,2,6a,6b,9,9,12a-heptamethyl-1,2,3,4,4a,5,6,6a,6b,7,8,8a,9,10,11,12,12a,12b,13,14b-icosahydropicene-4a-carboxylic acid	IC50	810 nM
CHEMBL4174865	IC50	1860 nM
3beta-hydroxyurs-12-en-28-oic acid	IC50	1900 nM
CHEMBL4160163	IC50	2010 nM
CHEMBL4170383	IC50	2470 nM
6-hydroxy-3-iodo-1-methyl-2-[3-[[2-oxo-2-(4-thiophen-3-ylanilino)acetyl]amino]phenyl]indole-5-carboxylic acid	IC50	2900 nM	US-9522881: Hydroxyindole carboxylic acid based inhibitors for oncogenic Src homology-2 domain containing protein tyrosine phosphatase-2 (SHP2)
CHEMBL2396718	IC50	2900 nM
CHEMBL4168082	IC50	3700 nM
CHEMBL4159748	IC50	4170 nM
CHEMBL2396719	IC50	4600 nM
ammonium N-{4-[4-ethoxy-2,2-bis(methoxycarbonyl)-4-oxobutyl]phenyl}sulfamate	IC50	4800 nM
ammonium N-{4-[3-methoxy-2-(methoxycarbonyl)-3-oxo-2-(3-phenylpropyl)propyl]phenyl}sulfamate	IC50	7700 nM
(4aS,6aS,6bR,10S,12aR,14bS)-10-Hydroxy-2,2,6a,6b,9,9,12a-heptamethyl-1,3,4,5,6,6a,6b,7,8,8a,9,10,11,12,12a,12b,13,14b-octadecahydro-2H-picene-4a-carboxylic acid	IC50	8800 nM
6-(Oxalyl-amino)-1H-indole-7-carboxylic acid	KI	20000 nM
2-(3-(dihydroxymethyl)naphthalen-2-ylamino)-2-oxoacetic acid	KI	37000 nM
2-oxalylamino-4,5,6,7-tetrahydrobenzo[b]thiophene-3-carboxylic acid	KI	41000 nM
CHEMBL3596431	IC50	43000 nM
5-iodo-2-(oxaloamino)benzoic acid	KI	49000 nM
2-(carboxyformamido)-5,7-dihydro-4H-thieno[2,3-c]pyran-3-carboxylic acid	KI	53000 nM
6-(carboxyformamido)-1H-indole-5-carboxylic acid	KI	56000 nM
2-(carboxyformamido)-4,5,6,7-tetrahydrothieno[2,3-c]pyridine-3-carboxylic acid	KI	59000 nM
ammonium N-[4-(2-{[(benzyloxy)carbonyl]amino}-3-ethoxy-2-(methoxycarbonyl)-3-oxopropyl)phenyl]sulfamate	IC50	82200 nM
2-(oxaloamino)benzoic acid	KI	160000 nM
2-(carboxyformamido)thiophene-3-carboxylic acid	KI	210000 nM
3-(Oxalyl-amino)-thiophene-2-carboxylic acid	KI	260000 nM
(S)-7-(1,1-Dioxo-1H-1lambda*6*-benzo[d]isothiazol-3-yloxymethyl)-2-(oxalyl-amino)-4,7-dihydro-5H-thieno[2,3-c]pyran-3-carboxylic acid	KI	489000 nM

ChEMBL bioactivities

5 potent at pChembl≥5 of 11 total, top 5 by pChembl (potency: 10 = 0.1 nM, 6 = 1 µM).

pChembl	Type	Value	Unit	Molecule
5.73	IC50	1860	nM	CHEMBL4174865
5.70	IC50	2010	nM	CHEMBL4160163
5.61	IC50	2470	nM	CHEMBL4170383
5.43	IC50	3700	nM	CHEMBL4168082
5.38	IC50	4170	nM	CHEMBL4159748

PubChem BioAssay actives

5 with measured affinity, of 67 total; 5 most potent distinct compounds. Largely complementary to BindingDB; screening values are coarse (µM, 4 dp), so sub-nM hits tie at the floor.

Compound	Assay	Type	Value	Unit
1-(3-chloro-4-fluorophenyl)-3-[5-[(2,4-dimethylphenoxy)methyl]-1,3,4-thiadiazol-2-yl]urea	1363112: Inhibition of recombinant human cytosolic PTPepsilon expressed in Escherichia coli BL21 (DE3) using E527-P-Q-pY530-Q-P-G-E-N-L536 as substrate after 60 mins by malachite green assay	ic50	1.8600	uM
2-(1,3-benzodioxol-5-yloxy)-N-[5-[(4-chlorophenoxy)methyl]-1,3,4-thiadiazol-2-yl]acetamide	1363112: Inhibition of recombinant human cytosolic PTPepsilon expressed in Escherichia coli BL21 (DE3) using E527-P-Q-pY530-Q-P-G-E-N-L536 as substrate after 60 mins by malachite green assay	ic50	2.0100	uM
1-[5-[(2,4-dimethylphenoxy)methyl]-1,3,4-thiadiazol-2-yl]-3-(4-methylphenyl)urea	1363112: Inhibition of recombinant human cytosolic PTPepsilon expressed in Escherichia coli BL21 (DE3) using E527-P-Q-pY530-Q-P-G-E-N-L536 as substrate after 60 mins by malachite green assay	ic50	2.4700	uM
2-(2-methoxyphenoxy)-N-[5-(phenoxymethyl)-1,3,4-thiadiazol-2-yl]acetamide	1363112: Inhibition of recombinant human cytosolic PTPepsilon expressed in Escherichia coli BL21 (DE3) using E527-P-Q-pY530-Q-P-G-E-N-L536 as substrate after 60 mins by malachite green assay	ic50	3.7000	uM
1-[5-[(4-butan-2-ylphenoxy)methyl]-1,3,4-thiadiazol-2-yl]-3-(2-methoxyphenyl)urea	1363112: Inhibition of recombinant human cytosolic PTPepsilon expressed in Escherichia coli BL21 (DE3) using E527-P-Q-pY530-Q-P-G-E-N-L536 as substrate after 60 mins by malachite green assay	ic50	4.1700	uM

CTD chemical–gene interactions

65 total (human), top 30 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
Valproic Acid	affects cotreatment, increases expression	6
Benzo(a)pyrene	affects methylation, increases expression	4
trichostatin A	increases expression, affects cotreatment	3
Estradiol	affects cotreatment, decreases expression, increases expression	3
Tetrachlorodibenzodioxin	affects cotreatment, increases expression, decreases expression	3
Tretinoin	increases expression	3
sodium arsenite	affects methylation, decreases expression	2
potassium chromate(VI)	affects cotreatment, decreases expression	2
Air Pollutants	affects expression, increases abundance, increases expression	2
Arsenic	affects expression, affects methylation, increases abundance, increases expression	2
Formaldehyde	decreases expression, increases expression	2
Nickel	increases expression	2
Ozone	increases abundance, increases expression, affects expression	2
Phenylmercuric Acetate	affects cotreatment, increases expression	2
Tamoxifen	affects expression, affects cotreatment, increases expression	2
Aflatoxin B1	affects methylation, increases expression	2
Raloxifene Hydrochloride	affects expression, affects cotreatment, increases expression	2
3-((6-(2-methoxyphenyl)pyrimidin-4-yl)amino)phenyl)methane sulfonamide	decreases expression	1
methylmercuric chloride	increases expression	1
triphenyl phosphate	affects expression	1
bisphenol A	affects cotreatment, increases methylation	1
sodium arsenate	increases abundance, increases expression	1
benzo(e)pyrene	decreases methylation	1
vanadyl sulfate	increases expression	1
isobutyl alcohol	affects cotreatment, increases abundance, increases expression	1
epigallocatechin gallate	affects cotreatment, decreases expression	1
di-n-butylphosphoric acid	affects expression	1
chromium hexavalent ion	decreases expression	1
CGP 52608	increases reaction, affects binding	1
2-palmitoylglycerol	increases expression	1

ChEMBL screening assays

23 unique, capped per target: 22 binding, 1 admet

Representative assays (with source publication via chembl_document):

Assay ID	Type	Description	Source paper
CHEMBL1050901	Binding	Inhibition of PTPRE	Knowledge-based characterization of similarity relationships in the human protein-tyrosine phosphatase family for rational inhibitor design. — *J Med Chem*
CHEMBL4626318	ADMET	Inhibition of PTPE (unknown origin) expressed in Escherichia coli BL21 using p-nitrophenyl phosphate as substrate measured after 30 mins by UV-vis spectrophotometric method	Highly Potent and Selective N-Aryl Oxamic Acid-Based Inhibitors for Mycobacterium tuberculosis Protein Tyrosine Phosphatase B. — *J Med Chem*

Clinical trials (associated diseases)

Via MONDO — disease-level, not drug-specific.

Predicted chemistry — Sugi Predict

The predicted patent-compound landscape for PTPRE across ~30M SureChEMBL compounds — explore on Sugi Predict.